Between January and June 2018, Russia imported 244.3 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 2% higher than that of the same period of 2017, and 52 bln RUB worth of in-bull drugs, which is in monetary terms 5% higher than that of the same period of 2017.

In physical terms, Russia imported 878.7 mln units of ready-made drugs, which is 7% lower than that of the same period of 2017, and 2.12 bln minimal dosage units (MDU) of in-bulk drugs, which is 0.4% lower than that of the same period of 2017. In total, Russia imported 18.5 bln MDUs, which is 4% lower than that of the same period of 2017.

In June 2018, Russia imported 45.5 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 2.7% higher than that of June 2017, and 9.3 bln RUB worth of in-bulk drugs, which is 29% higher than that of June 2017.

Among the top 20 ready-made drugs with the best dynamics are antivirals for HIV, in particular Tivicay (a 20 times increase) and Eviplera (a 3 times increase.) As for in-bulk drugs, the leaders are Revlimid (a nearly 200 times increase) and Concor (a 16 times increase.) Anti-tumor drug Keytruda, which is packaged on Ortat (R-Pharm plant), is also worth mentioning, its import has increased by 6.5 times.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – June 2018)